AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis

AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director; astrid.hilde.myrset@algipharma.com

April 2011

US Department of Defense supports an AlgiPharma initiated in vivo wound healing study on OligoG

AlgiPharma has together with Prof. Chandan Sen, at Ohio State University embarked on a study to investigate the effects of OligoG in a unique biofilm infected in vivo wound healing model.

For further information, please contact:
Philip D. Rye R&D Director; phil.rye@algipharma.com

August 2010

AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases

OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.

Read more ClinicalTrials.gov

For more information contact:
Yngvar P. Berg, CEO; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director; astrid.hilde.myrset@algipharma.com

January 2010

AlgiPharma granted permission to start Phase I trials in Cystic Fibrosis

A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), Oligo-G CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.

For more information contact:
Yngvar P. Berg, CEO, +47 90044903; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director, +47 93026094; astrid.hilde.myrset@algipharma.com

September 2009

AlgiPharma wins NFR funding for basic research projects on biofilms

The Research Council of Norway (Norges Forskningsråd (NFR)) has awarded AlgiPharma grants for two new projects “Biofilm” and “Epipharm II” representing a continuation and expansion of the NFR support for AlgiPharma’s alginate oligomer research efforts. These grants are administered under the NFR program for User directed Innovation Arena.

For further information, please contact:
Philip D. Rye R&D Director, +47 97503033; phil.rye@algipharma.com

June 2008

AlgiPharma’s medicinal alginate product gains Orphan Drug Status for Cystic Fibrosis Treatment

AlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. The European Medicines Agency’s Committee for Orphan Medicinal Products recommended that AlgiPharma’s application be accepted by the Commission of the European Communities. The Commission gave final approval on September 14th.

For more information contact:
Yngvar P. Berg, CEO, +47 90044903; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director, +47 93026094; astrid.hilde.myrset@algipharma.com

September 2007

AlgiPharma Established

On the initiative of FMC BioPolymer AS, AlgiPharma was established, financed and began operating as an independent company. AlgiPharma is a biopharmaceutical company that aims to develop medicinal products within the areas of respiratory diseases, wound healing and other infectious diseases.

For further information, please contact:
Arne Dessen, Chairman of Board, +47 95170278; arne.dessen@algipharma.com
Yngvar P. Berg, CEO, +47 90044903; yngvar.berg@algipharma.com

August 2006